Market Overview

UPDATE: H.C. Wainwright & Co. Initiates Coverage on Seattle Genetics on Good Potential for Adcetris

Share:
Related SGEN
Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma
Seattle Genetics Announces Data Presentations at ASCO Related to ADCETRIS in AETHERA Post-Transplant Consolidation Setting
Seattle Genetics (SGEN) Loss Widens in Q2, Ups 2015 View - Analyst Blog (Zacks)

In a report published Monday, H.C. Wainwright & Co. analyst Andrew S. Fein initiated coverage on Seattle Genetics (NASDAQ: SGEN) with a Buy rating and $65.00 price target.

In the report, H.C. Wainwright & Co. noted, “We believe that Adcetris, anti-CD30-targeted antibody drug conjugate (ADC), already approved for the treatment of refractory Hodgkin's lymphoma and anaplastic large cell lymphoma, could show further robust activity allowing it to move into new cancer indications and earlier lines of therapy. While Street expectations for SGEN are high, we also believe there could be attractive upside based on prospects for Adcetris, other ADCs, and the technology platform.”

Seattle Genetics closed on Friday at $51.78.

Latest Ratings for SGEN

DateFirmActionFromTo
May 2015Credit SuisseAssumesOutperform
Feb 2015JP MorganMaintainsNeutral
Oct 2014Cantor FitzgeraldUpgradesSellHold

View More Analyst Ratings for SGEN
View the Latest Analyst Ratings

Posted-In: Andrew S. Fein H.C. Wainwright & Co.Analyst Color Initiation Analyst Ratings

 

Related Articles (SGEN)

Get Benzinga's Newsletters